Regional Clustering of Shared Neutralization Determinants on Primary Isolates of Clade C Human Immunodeficiency Virus Type 1 from South Africa
Open Access
- 1 March 2002
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 76 (5) , 2233-2244
- https://doi.org/10.1128/jvi.76.5.2233-2244.2002
Abstract
Clade C is one of the most prevalent genetic subtypes of human immunodeficiency virus type 1 (HIV-1) in the world today and one of the least studied with respect to neutralizing antibodies. Most information on HIV-1 serology as it relates to neutralization is derived from clade B. Clade C primary isolates of HIV-1 from South Africa and Malawi were shown here to resemble clade B isolates in their resistance to inhibition by soluble CD4 and their sensitivity to neutralization by human monoclonal antibody immunoglobulin G1b12 and, to a lesser extent, 2F5. Unlike clade B isolates, however, all 16 clade C isolates examined resisted neutralization by 2G12. Infection with clade C HIV-1 in a cohort of female sex workers in South Africa generated antibodies that neutralized the autologous clade C isolate and T-cell-line-adapted (TCLA) strains of clade B. Neutralization of clade B TCLA strains was much more sensitive to the presence of autologous gp120 V3 loop peptides compared to the neutralization of clade C isolates in most cases. Thus, the native structure of gp120 on primary isolates of clade C will likely pose a challenge for neutralizing antibody induction by candidate HIV-1 vaccines much the same as it has for clade B. The autologous neutralizing antibody response following primary infection with clade C HIV-1 in South Africa matured slowly, requiring at least 4 to 5 months to become detectable. Once detectable, extensive cross-neutralization of heterologous clade C isolates from South Africa was observed, suggesting an unusual degree of shared neutralization determinants at a regional level. This high frequency of cross-neutralization differed significantly from the ability of South African clade C serum samples to neutralize clade B isolates but did not differ significantly from results of other combinations of clade B and C reagents tested in checkerboard assays. Notably, two clade C serum samples obtained after less than 2 years of infection neutralized a broad spectrum of clade B and C isolates. Other individual serum samples showed a significant clade preference in their neutralizing activity. Our results suggest that clades B and C are each comprised of multiple neutralization serotypes, some of which are more clade specific than others. The clustering of shared neutralization determinants on clade C primary HIV-1 isolates from South Africa suggests that neutralizing antibodies induced by vaccines will have less epitope diversity to overcome at a regional level.Keywords
This publication has 128 references indexed in Scilit:
- Identification of HIV Type 1 Intersubtype Recombinants in South Africa Using env and gag Heteroduplex Mobility AssaysAIDS Research and Human Retroviruses, 2000
- Safety of multiple daily applications of COL-1492, a nonoxynol-9 vaginal gel, among female sex workersAIDS, 2000
- A Predominantly HIV Type 1 Subtype C-Restricted Epidemic in South African Urban PopulationsAIDS Research and Human Retroviruses, 1999
- Sequence Note: Variation in HIV Type 1 V3 Region env Sequences from MozambiqueAIDS Research and Human Retroviruses, 1998
- Genetic Characterization of HIV Type 1 from Migrant Workers in Three South African Gold MinesAIDS Research and Human Retroviruses, 1998
- CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5Nature, 1996
- The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 IsolatesPublished by Elsevier ,1996
- CC CKR5: A RANTES, MIP-1α, MIP-1β Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1Science, 1996
- Antibody neutralization of HIV-1Immunology Today, 1996
- Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptorCell, 1987